Core Viewpoint - Nvidia's market share in China has plummeted to 0%, with no sales of its AI chips, as confirmed by CEO Jensen Huang [1][3]. Group 1: Market Dynamics - Nvidia once held a 95% market share in China, but it has now been completely overtaken by domestic competitors [1]. - The Chinese AI chip market is dominated by local companies such as Huawei, Alibaba, and Cambricon, which have developed competitive products that outperform Nvidia's offerings [3][5]. - Huawei's latest AI accelerator card, Atlas 350, features the Ascend 950PR processor, which is 2.87 times more powerful than Nvidia's H20 [3]. Group 2: Competitor Landscape - Alibaba's self-developed GPU chip, Zhenwu 810E, has shipped over 470,000 units and is used by more than 400 domestic enterprises, matching the performance of Nvidia's H20 [3]. - Cambricon has achieved profitability in 2025, earning over 2 billion yuan, and has significantly replaced Nvidia's chips in the market [5]. - Haiguang Information has developed its own DCU chip, which also matches the performance of Nvidia's H20 and has been widely adopted by domestic companies [5]. Group 3: Emerging Players - The "GPU Four Little Dragons" including Moore Threads, Muxi Technology, Biran Technology, and Tian Shu Zhixin have successfully gone public, securing substantial funding for research and development [7]. - Numerous other GPU companies are entering the AI sector, contributing to the trend of domestic substitution of Nvidia's chips [8]. Group 4: Industry Trends - The tightening of U.S. export controls on AI chips has led to a strong emphasis on "domestic substitution" within China's AI chip industry, with more companies opting for local solutions over Nvidia's products [8].

Core Viewpoint - The strategic cooperation agreement between Innovent Biologics and Eli Lilly has been effective since March 24, 2026, aimed at advancing new drug development in oncology and immunology, without involving equity transactions [1][3]. Group 1: Agreement Details - The agreement was initially announced on February 8, 2026, and is the seventh collaboration between the two companies, enhancing their long-term partnership to deliver innovative drugs to global patients [1][3]. - Innovent Biologics clarified that the agreement is not a merger or acquisition, emphasizing that it is solely focused on research collaboration and does not alter the company's independent operations or equity structure [1][3]. Group 2: Financial Aspects - Innovent Biologics will receive an upfront payment of $350 million, with the potential to earn up to approximately $8.5 billion in milestone payments related to research, regulatory, and commercialization achievements [2][4]. - The company retains all rights to the relevant projects in Greater China while Eli Lilly obtains exclusive global development and commercialization rights outside of this region [2][4]. Group 3: Company Background - Founded in 2011, Innovent Biologics focuses on the research, production, and sales of innovative drugs in major disease areas such as oncology, autoimmune diseases, metabolism, and ophthalmology [2][5]. - The company has 18 products approved for market, with 4 new drug molecules in Phase III or pivotal clinical studies, and an additional 15 new drug candidates in clinical research [2][5]. - Innovent Biologics has established over 30 strategic collaborations with international partners, including Eli Lilly, Roche, Takeda, Sanofi, Incyte, and MD Anderson Cancer Center [2][5].

Core Viewpoint - The Iranian parliamentary speaker, Ghalibaf, and foreign minister, Zarif, have been temporarily removed from the U.S. and Israeli target lists as the U.S. seeks to engage in high-level negotiations to end the conflict [1][2]. Group 1 - Ghalibaf and Zarif's removal from the target list is set for a duration of 4 to 5 days [1][2]. - The U.S. has indicated a willingness to engage in dialogue with Iran to end the war, suggesting that Ghalibaf may be a potential interlocutor [1][2]. - Ghalibaf has denied any dialogue with the U.S., while Zarif stated that there are no talks or negotiations between Iran and the U.S. [1][2].

Core Viewpoint - The article discusses the strategic opportunities and challenges faced by Dow in the Chinese market, emphasizing the importance of sustainable development and alignment with China's "dual carbon" goals [1][8][23]. Group 1: Market Opportunities - The Chinese market is characterized by significant policy support and demand in sectors such as new energy, semiconductors, and high-end manufacturing, presenting key opportunities for Dow [3][18]. - Dow has identified the potential for transforming cutting-edge materials science technologies into scalable and sustainable solutions within the Chinese market [4][19]. - The company is leveraging its long-term expertise in high-performance materials to meet the increasing safety, reliability, and sustainability requirements in the new energy sector [4][20]. Group 2: Sustainable Development Strategy - Dow aims to reduce its global carbon emissions by 5 million tons annually by 2030, which represents a 15% reduction from 2020 levels, and to achieve carbon neutrality by 2050 [8][23]. - Approximately 90% of Dow's R&D projects are focused on sustainability, with a goal to reach 100% [8][23]. - The company is actively engaging in circular economy initiatives, including recycling plastic waste and developing sustainable materials that balance performance and environmental impact [9][24]. Group 3: Local Adaptation and Innovation - Dow is adapting to the rapidly changing regulatory environment and consumer demands in China by maintaining a long-term strategic focus while enhancing competitiveness [6][21]. - The company emphasizes the integration of global capabilities with local insights to develop innovative solutions tailored to the Chinese market [7][22]. - Dow is committed to collaborating with local customers and partners to drive application-oriented innovation in sectors such as artificial intelligence and new energy [14][29]. Group 4: Future Outlook - Dow recognizes China's evolving role in global supply chains and aims to deepen its presence in the market by enhancing supply chain reliability and sustainability [13][28]. - The company plans to invest in circular materials and green design to support clients' transitions towards sustainability and contribute to China's "dual carbon" goals [14][29]. - Dow's focus on long-term partnerships and co-creation with clients and industry stakeholders is seen as essential for navigating future market dynamics [7][22].

Core Viewpoint - China COSCO Shipping International (00517) experienced a decline of over 4% in stock price following its earnings report, with a current price of HKD 6.54 and a trading volume of HKD 28.83 million [1][4] Financial Performance - For the fiscal year ending December 31, 2025, the company reported a revenue increase of 2% to HKD 3.706 billion, primarily driven by higher income from the coatings and ship trading agency segments [1][4] - The profit attributable to equity holders rose by 9% to HKD 771 million, attributed to increased revenue, profits from a joint venture, and net foreign exchange gains [1][4] - Basic and diluted earnings per share increased by 9% to HKD 0.526 [1][4] Dividend Proposal - The board of directors proposed a final dividend of HKD 0.19 per share and an additional special dividend of HKD 0.10 per share [1][4]

Core Viewpoint - Citigroup has downgraded the profit forecast for Beijing Enterprises Water Group (00371) for 2026 to 2027 by 9% to 11% due to a decrease in construction and technical service revenues, but has raised the target price from HKD 2.85 to HKD 3.05 based on improved free cash flow and rolling forecasts, maintaining a "Buy" rating [1][4]. Financial Performance - The company's net profit for 2025 is expected to decline by 6.9% to RMB 1.562 billion, primarily due to a reduction in non-cash construction income and impairment related to asset disposals [1][4]. - Revenue for 2025 is projected to drop by 9.1% to RMB 22.062 billion, with non-cash construction income's share decreasing from 14.2% to 7.4% [1][4]. - Operating income is expected to decrease by 1.9% due to the disposal of certain consulting businesses [1][4]. Cash Flow and Dividends - Free cash flow is anticipated to surge 2.5 times year-on-year to RMB 5.2 billion, benefiting from the collection of non-core project disposals and reduced capital expenditures [1][4]. - The company plans to exit more loss-making projects, with management expecting free cash flow to reach RMB 3 billion in 2026 and capital expenditure budgeted at no more than RMB 4 billion [1][4]. - The company is projected to increase its dividend per share by 3.1% to HKD 0.166 for 2025, with a payout ratio of 98%, and a forecasted dividend yield of 6.1% for 2026 [1][4]. Revenue Breakdown and Margins - The gross margin is expected to expand by 1.4 percentage points to 38.5%, driven by an increase in the share of revenue from wastewater treatment services [1][4]. - Total revenue for 2026 is expected to decline by 7%, with construction and technical service revenues projected to fall by 38% and 35% respectively, while urban resource service revenue is expected to remain stable, and wastewater and water supply revenues are expected to decrease by 3% [1][4].

Core Insights - China Taiping's total investment income for 2025 is projected to be HKD 66.8 billion, with net investment income reaching HKD 53 billion, reflecting a year-on-year growth of 5.2% [1][2][3] - The proportion of net investment income has increased to 79.3%, up by 3.7 percentage points from the previous year, indicating a greater reliance on stable sources such as dividends and interest, while reducing dependence on volatile capital gains [1][3] Investment Strategy - China Taiping has increased its investment in A-shares, with equity assets rising by 3.4 percentage points compared to the end of 2024, successfully meeting the requirement of investing 30% of new premiums in A-shares [1][3] - The company emphasizes a management approach of "one persistence and four reinforcements" in response to market volatility, focusing on long-term investment strategies and collective decision-making [2][3] Future Outlook - In 2026, China Taiping aims to leverage its unique advantages of ample and long-term insurance funds to act as a stabilizing force in the capital market [2][3] - The equity investment strategy will focus on new productive forces and high-dividend assets to manage volatility, while the fixed-income strategy will prioritize allocation over trading, locking in returns at relatively high interest rates [2][3] - For overseas investments, the company will prioritize risk prevention, focusing on high-grade credit bonds in fixed income and Hong Kong stocks in equity [2][3]

Core Viewpoint - Reflection AI, a startup supported by Nvidia, is negotiating to raise $2.5 billion at a valuation of $25 billion, reflecting its pre-funding valuation [1] Group 1: Company Overview - Reflection AI is in discussions to secure $2.5 billion in funding [1] - The proposed valuation of $25 billion is based on the company's pre-investment worth [1] Group 2: Investment Details - JPMorgan is considering participation in this funding round through its Security and Resiliency Initiative [1]

Group 1 - Vanke is reportedly seeking to extend the maturity of its bonds again while also exploring an overall restructuring plan [1]

Market Overview - Hong Kong stocks opened lower on March 26, following two days of gains, with major internet stocks experiencing a pause in their upward momentum. Alibaba-W fell over 3%, Meituan-W dropped more than 2%, Tencent Holdings slightly decreased by 0.89%, while Xiaomi Group-W rose against the trend. The Hong Kong Internet ETF Huabao (513770) saw a decline of 1.14% in its market price [1][7]. Regulatory Impact - A significant turning point occurred in the food delivery market as the National Market Regulation Administration circulated a commentary titled "The Food Delivery War Should End," interpreted as a clear signal from regulators to halt "involutionary" price wars. Following this, Meituan-W and Alibaba-W surged, with southbound funds recording a net purchase exceeding 20 billion yuan throughout the day. This series of anti-involution policies is expected to cool down price wars among major platforms, leading to performance recovery expectations [3][9]. Industry Outlook - The fund manager of the Hong Kong Internet ETF Huabao, Feng Chen, noted that recent price increases from major model manufacturers and cloud service providers indicate significant upward elasticity in the pricing of internet leaders' computing power and cloud services amid changing demand. Coupled with the diminishing competition from involution, multiple positive factors are expected to resonate, leading to a gradual improvement in the fundamentals of Hong Kong internet stocks starting from the second quarter. Valuation and positioning are seen as safeguards for future elasticity [3][9]. Investment Tools - For investors looking to reduce volatility while remaining optimistic about Hong Kong technology stocks, the Hong Kong Large Cap 30 ETF (520560) is highlighted as the first in the market to adopt a "technology + dividend" strategy. This ETF includes high-elasticity tech stocks like Alibaba, as well as stable high-dividend stocks from banks and insurance companies, making it an ideal long-term investment tool for the Hong Kong market [4][10]. ETF Details - The Hong Kong Internet ETF Huabao (513770) and its linked funds (Class A 017125; Class C 017126) passively track the CSI Hong Kong Internet Index, with the top ten weighted stocks comprising major tech giants like Alibaba-W and Tencent Holdings, as well as various AI application companies. The ETF offers T+0 trading and good liquidity [3][9].